Tectonic Therapeutic, Inc.'s stock surged 120% on positive Phase 1b data for TX45 in treating PH-HFpEF, offering a potential ...

With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...

Eli Lilly (LLY) closed the latest trading day at $804.99, indicating a -0.39% change from the previous session's end. The stock trailed the S&P 500, which registered a daily gain of 0.92%. At the same ...

GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

A new study led by Western researchers found frequent treatment with intranasal oxytocin – a hormone in the brain associated ...

Vertex's lineup will look transformed in five years, and the company should continue performing well beyond that time. It's ...

US-based pharmaceutical giant Eli Lilly is focusing on weight loss medications like Mounjaro (tirzepatide), which has proven ...

The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.

Eli Lilly (NYSE: LLY) sells a broad variety of drugs ... as declines in coronavirus testing hurt sales in diagnostics -- ...

Her doctor prescribed the cheaper, generic version of the weight-loss drug after her insurer refused to cover Zepbound, the ...

Kyverna Therapeutics said it named Naji Gehchan as its chief medical and development officer. The clinical-stage biopharmaceutical company on Tuesday said that Gehchan comes from Eli Lilly, where he ...

Lilly has also submitted marketing applications for Mirikizumab-mrkz in Crohn’s disease around the globe, including in the ...